Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study-Reference-Cited by-同舟云学术

Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study

Published:2019-04 Issue: Volume:130 Page:149-155
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Schmid S.,Klingbiel D.,Aeppli S.,Britschgi C.,Gautschi O.,Pless M.,Rothschild S.^ORCID,Wannesson L.,Janthur W.,Foerbs D.,Demmer I.,Jochum W.,Früh M.^ORCID

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference28 articles.

1. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N. Engl. J. Med.,2009

2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

3. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations;Sequist;J. Clin. Oncol.,2013

4. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial;Wu;Lancet Oncol.,2014

5. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial;Park;Lancet Oncol.,2016

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with driver-gene negative advanced non-small cell lung cancer;BMC Cancer;2024-05-07

2. Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study;JTO Clinical and Research Reports;2024-05

3. Outcomes of extracranial stereotactic body radiation therapy for induced oligometastatic non-small cell lung cancer on novel systemic therapy;Translational Lung Cancer Research;2024-03

4. Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study;Lung Cancer;2024-01

5. Local control strategies for management of NSCLC with oligoprogressive disease;Cancer Treatment Reviews;2023-11